Literature DB >> 25405500

Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes.

Martha M Sklavos1, Pamela Stratton, Neelam Giri, Blanche P Alter, Sharon A Savage, Ligia A Pinto.   

Abstract

CONTEXT: Previously, reduced levels of anti-Müllerian hormone (AMH), a circulating marker of ovarian reserve, were found in females with Fanconi anemia (FA). FA, dyskeratosis congenita (DC), and Diamond-Blackfan anemia (DBA) are inherited bone marrow failure syndromes (IBMFS) associated with high risks of bone marrow failure, leukemia, and solid tumors.
OBJECTIVE: The objective of the study was to assess AMH levels in females with DC or DBA. DESIGN AND
SETTING: This observational study used the National Cancer Institute's inherited bone marrow failure syndrome cohort at the National Institutes of Health Clinical Center. PARTICIPANTS: The study included females with DC, unaffected female relatives of patients with DC, females with DBA, unaffected female relatives of patients with DBA, and unrelated healthy female volunteers younger than 41 years of age. MAIN OUTCOME MEASURE: Serum AMH levels were measured.
RESULTS: Females with DC had significantly lower levels of AMH (median 0.55 ng/mL) compared with unaffected relatives (median 2.28 ng/mL, P = .004) or unrelated healthy volunteers (median 2.69 ng/mL, P = .005). Females with DBA showed a nonsignificant trend for lower levels of AMH (median 0.89 ng/mL) compared with unaffected relatives (median 1.71 ng/mL, P = .21) or unrelated healthy volunteers (P = .11). Patients with DC and DBA had significantly higher levels of AMH (P = .013, P = .003) compared with FA (median 0.05 ng/mL).
CONCLUSIONS: Our findings suggest that women with IBMFS have lower levels of AMH than unaffected women. This AMH deficiency could be a primary ovarian defect or a consequence of the pathophysiology of the syndromes. Additional studies of AMH and ovarian function in women with IBMFS are warranted to better understand the underlying biology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25405500      PMCID: PMC4318906          DOI: 10.1210/jc.2014-2838

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

1.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg
Journal:  Br J Haematol       Date:  2010-04-30       Impact factor: 6.998

Review 2.  Mouse models of Fanconi anemia.

Authors:  Kalindi Parmar; Alan D'Andrea; Laura J Niedernhofer
Journal:  Mutat Res       Date:  2009-04-10       Impact factor: 2.433

3.  A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II).

Authors:  A M Wallace; S A Faye; R Fleming; S M Nelson
Journal:  Ann Clin Biochem       Date:  2011-05-31       Impact factor: 2.057

4.  Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry.

Authors:  Adrianna Vlachos; Philip S Rosenberg; Eva Atsidaftos; Blanche P Alter; Jeffrey M Lipton
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

5.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

6.  Individual serum levels of anti-Müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study.

Authors:  Casper P Hagen; Lise Aksglaede; Kaspar Sørensen; Annette Mouritsen; Anna-Maria Andersson; Jørgen Holm Petersen; Katharina M Main; Anders Juul
Journal:  Hum Reprod       Date:  2012-01-02       Impact factor: 6.918

Review 7.  Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve.

Authors:  R Hampl; M Šnajderová; T Mardešić
Journal:  Physiol Res       Date:  2010-11-29       Impact factor: 1.881

Review 8.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 9.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

Review 10.  Primary ovarian insufficiency: a more accurate term for premature ovarian failure.

Authors:  Corrine K Welt
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-29       Impact factor: 3.478

View more
  10 in total

1.  Pregnancy outcomes in inherited bone marrow failure syndromes.

Authors:  John M Gansner; Maureen M Achebe; Kathryn J Gray; Revital Yefidoff-Freedman; Elena Labovitis; Aric Parnes; Jean M Connors; Nathan T Connell; Marie N Discenza; Robert I Handin; Nancy Berliner; Akiko Shimamura; Elizabeth S Ginsburg; Nicole A Smith
Journal:  Blood       Date:  2017-08-10       Impact factor: 22.113

2.  Pregnancies in patients with inherited bone marrow failure syndromes in the NCI cohort.

Authors:  Neelam Giri; Pamela Stratton; Sharon A Savage; Blanche P Alter
Journal:  Blood       Date:  2017-08-24       Impact factor: 22.113

Review 3.  Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.

Authors:  Andrew C Dietz; Sharon A Savage; Adrianna Vlachos; Parinda A Mehta; Dorine Bresters; Jakub Tolar; Carmem Bonfim; Jean Hugues Dalle; Josu de la Fuente; Roderick Skinner; Farid Boulad; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-19       Impact factor: 5.742

4.  The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.

Authors:  Jiangxue Qu; Yuehan Li; Shujie Liao; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Impaired reproductive function and fertility preservation in a woman with a dyskeratosis congenita.

Authors:  LeRoy G Robinson; Ricardo Pimentel; Fang Wang; Yael G Kramer; Damla C Gonullu; Suneet Agarwal; Paula A Navarro; David McCulloh; David L Keefe
Journal:  J Assist Reprod Genet       Date:  2020-05-13       Impact factor: 3.412

Review 6.  Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.

Authors:  Andrew C Dietz; Parinda A Mehta; Adrianna Vlachos; Sharon A Savage; Dorine Bresters; Jakub Tolar; Farid Boulad; Jean Hugues Dalle; Carmem Bonfim; Josu de la Fuente; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-20       Impact factor: 5.742

7.  Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies.

Authors:  Jovana Lekovich; Alexandre L S Lobel; Joshua D Stewart; Nigel Pereira; Isaac Kligman; Zev Rosenwaks
Journal:  J Assist Reprod Genet       Date:  2016-03-04       Impact factor: 3.412

8.  Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.

Authors:  Melissa A Merideth; Laura A Harney; Nina Vyas; Averyl Bachi; Ann Garrity Carr; D Ashley Hill; Louis P Dehner; Kris Ann P Schultz; Douglas R Stewart; Pamela Stratton
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

9.  Gynaecological and reproductive health of women with telomere biology disorders.

Authors:  Neelam Giri; Blanche P Alter; Sharon A Savage; Pamela Stratton
Journal:  Br J Haematol       Date:  2021-05-21       Impact factor: 8.615

Review 10.  Fanconi anemia and dyskeratosis congenita/telomere biology disorders: Two inherited bone marrow failure syndromes with genomic instability.

Authors:  Moisés Ó Fiesco-Roa; Benilde García-de Teresa; Paula Leal-Anaya; Renée van 't Hek; Talia Wegman-Ostrosky; Sara Frías; Alfredo Rodríguez
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.